Roche told investors on Monday that it plans to make significant cuts to both the cost and time it takes for it to develop ...

Some oncologists are turning to GLP-1 agents to help patients shed excess pounds, with the goal of improving cancer outcomes.

People with type 2 diabetes and obesity who develop kidney disease may benefit more from bariatric surgery than from GLP-1 ...

Maez Waibel lost more than 30 pounds in nine months on the new weight-loss drugs, sparking a substantial improvement in ...

BioAge Labs, a biopharmaceutical startup focused on obesity drugs, is looking to raise nearly $200 million in its recently ...

Is Novo Nordisk helping Americans save taxpayer money or ripping them off? The company’s CEO is scheduled to testify Tuesday ...

Sen. Bernie Sanders argues that Novo Nordisk charges Americans substantially higher prices for its drugs than it does for ...

Since being deemed a public health emergency in 2017, opioids are responsible for 72% of drug overdose deaths in the United ...

On Tuesday, congressional leaders spent two hours taking to task Novo Nordisk Chief Executive Officer Lars Fruergaard Jørgensen over the high price of the company’s diabetes and obesity drugs, Ozempic ...

Semaglutide, the underlying drug marketed as Ozempic and Wegovy, works by mimicking a hormone that triggers the body to feel ...

Semaglutide, a drug used for diabetes and weight loss, might help reduce opioid overdoses in people with OUD and T2D.